Informed written consent for entry into the study should be obtained prior to randomization. All eligibility criteria and consent form will be checked, and the stratification factors stated before treatment is allocated. The patient will be randomized to long infusional gemcitabine (L) or 30- minute short infusion gemcitabine (S), and allocated a trial number. The design will involve equal allocation of patients to the two treatments. Confirmation fax will be sent to the investigator.